Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a leading biotechnology company known for its innovative approach to drug development. Established in 1988, the company is headquartered in Tarrytown, New York with over 7,000 employees worldwide. Regeneron is dedicated to transforming patients' lives through science and its mission is to consistently deliver new medicines with significant therapeutic benefits.
The company's portfolio includes seven FDA-approved medications – Praluent (cholesterol treatment), Kevzara (rheumatoid arthritis treatment), Libtayo (cutaneous squamous cell carcinoma treatment), Eylea (macular degeneration treatment), Dupixent (eczema, asthma, and nasal polyps treatment), Zaltrap (colorectal cancer treatment) and Arcalyst (autoinflammatory conditions treatment). Meanwhile, Regeneron’s research and development team is continually working on developing innovative new treatments for a wide range of diseases.
Regeneron is perhaps best known for its genetics-driven approach to drug discovery and development. Its technologies and capabilities include VelociGene, used for validating potential drug targets; VelociMouse; used for shortening the timeframe for drug testing and VelocImmune, a tool which helps develop fully human monoclonal antibodies.
Given the ongoing COVID-19 pandemic, it's important to note that Regeneron's antiviral cocktail, REGEN-COV (Casirivimab with Imdevimab), has been authorized under an emergency use authorization by the FDA for the treatment and prevention of COVID-19.
Regeneron has been recognized repeatedly for its commitment to innovation and excellence. It was named to Forbes' World's Most Innovative Companies List and Fortune's World's Most Admired Companies List. Notably, in 2020, Science Magazine named Regeneron as the top employer in the global biopharmaceutical industry for the third year in a row.
Regeneron's co-founder, President and Chief Scientific Officer, Dr. George Yancopoulos, holds more than 100 patents and is the highest number patent-holder among New York State's biotechnology professionals. Meanwhile, other leaders of the company have been recognized for their contributions to healthcare, including CEO Leonard Schleifer, who was named EY’s Entrepreneur of the Year in 2019.
In conclusion, Regeneron Pharmaceuticals is a leader in biotechnology industry known for its genetics-driven approach and is committed to harnessing the power of science to bring new hope and therapies to patients across the world.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Sarepta Therapeutics' stock dropped 7.2% despite settling a patent infringement lawsuit with REGENXBIO and the University of Pennsylvania regarding ELEVIDYS and AAVrh74-based gene therapies. The settlement, involving a US$39.0 million payment, provides Sarepta with freedom to operate but shifts investor focus back to ELEVIDYS's clinical performance, safety, and commercial execution. Analysts offer varying forecasts for Sarepta's future revenue and earnings, with some predicting a significant upside while others remain cautious due to reliance on ELEVIDYS.
Wall Street Zen has upgraded Adicet Bio (NASDAQ:ACET) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $46.80. The clinical-stage biotechnology company's shares opened up 9.1% at $9.02, despite missing its latest earnings estimate. Institutional investors and hedge funds own a significant 83.89% of the company.
REGENXBIO Inc. reported new three-year follow-up data from its ALTITUDE trial, showing that six out of ten higher-dose participants experienced a significant improvement in diabetic retinopathy severity. This data supports the ongoing Phase IIb/III NAAVIGATE trial, which is testing the gene therapy sura-vec against a sham control. The company expects topline results from its ATMOSPHERE and ASCENT trials for wet age-related macular degeneration in Q4 2026 and projects a cash runway into Q4 2027.
Sanofi is diversifying its revenue streams beyond its top-selling immunology drug, Dupixent, which currently accounts for 42% of its first-half 2026 revenues. The company is experiencing strong uptake for new medicines like Altuviiio, Ayvakit, and Sarclisa, with new and acquired drug sales rising 48.3% in Q2. Sanofi anticipates its new pharma launches to generate approximately €10 billion in annual sales by 2030, aiming to broaden its revenue base and decrease its reliance on Dupixent.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced it will release its third-quarter 2026 financial and operating results on October 30, 2026, before the U.S. financial markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time on the same day to discuss the results. Interested participants can access the webcast via Regeneron's investor relations page or register in advance for telephone participation.
Regeneron Pharmaceuticals (REGN) is facing a securities class action related to its Phase III Fianlimab Libtayo trial, leading to increased risk perception despite strong past performance. The company is considered about 4% undervalued by Simply Wall St, trading at US$801.82 against a fair value estimate of US$833, supported by a broad and advancing pipeline. However, P/E ratio analysis shows the stock trading slightly above the US Biotech average, suggesting either execution risk or room for re-rating by the market.
Merck announced that both doses of its drug remigromig met the BRUNELLO trial's noninferiority goal against ranibizumab for diabetic macular edema. While the drug showed promise in vision improvement, the company flagged higher rates of eye complications and adverse event discontinuations compared to the control group. More detailed safety and efficacy data are expected to be presented at the American Academy of Ophthalmology meeting on October 10.